GAMMA Investing LLC Boosts Stock Position in Insulet Co. (NASDAQ:PODD)

GAMMA Investing LLC boosted its holdings in shares of Insulet Co. (NASDAQ:PODD) by 44.0% during the fourth quarter, Holdings Channel.com reports. The firm owned 2,424 shares of the medical instruments supplier’s stock after acquiring an additional 741 shares during the period. GAMMA Investing LLC’s holdings in Insulet were worth $633,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Baillie Gifford & Co. raised its position in shares of Insulet by 20.7% during the 3rd quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier’s stock valued at $529,669,000 after buying an additional 389,639 shares in the last quarter. Geode Capital Management LLC increased its stake in Insulet by 1.3% during the third quarter. Geode Capital Management LLC now owns 1,738,601 shares of the medical instruments supplier’s stock worth $403,339,000 after acquiring an additional 22,850 shares during the last quarter. Clearbridge Investments LLC raised its position in Insulet by 6.0% during the second quarter. Clearbridge Investments LLC now owns 1,339,763 shares of the medical instruments supplier’s stock valued at $270,364,000 after purchasing an additional 75,526 shares during the period. American Century Companies Inc. lifted its stake in shares of Insulet by 18.7% in the 2nd quarter. American Century Companies Inc. now owns 885,669 shares of the medical instruments supplier’s stock valued at $178,728,000 after purchasing an additional 139,246 shares during the last quarter. Finally, Westfield Capital Management Co. LP boosted its holdings in shares of Insulet by 27.6% in the 3rd quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock worth $175,697,000 after purchasing an additional 163,388 shares during the period.

Wall Street Analyst Weigh In

PODD has been the topic of several recent research reports. Piper Sandler increased their price target on Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a report on Tuesday, September 17th. Citigroup increased their target price on shares of Insulet from $283.00 to $310.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Canaccord Genuity Group lifted their price target on shares of Insulet from $269.00 to $304.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. Raymond James increased their price objective on shares of Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a research report on Monday, October 14th. Finally, TD Cowen boosted their target price on Insulet from $264.00 to $324.00 and gave the company a “buy” rating in a research report on Friday. Three research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $272.81.

Insulet Stock Up 3.7 %

Shares of Insulet stock opened at $266.30 on Friday. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The stock has a market cap of $18.68 billion, a price-to-earnings ratio of 45.60, a PEG ratio of 4.12 and a beta of 1.21. The firm’s 50-day moving average is $260.30 and its two-hundred day moving average is $227.97. Insulet Co. has a 1 year low of $160.19 and a 1 year high of $279.77.

Insider Transactions at Insulet

In related news, CAO Lauren Budden sold 915 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the transaction, the chief accounting officer now owns 5,733 shares of the company’s stock, valued at $1,580,129.46. The trade was a 13.76 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.47% of the company’s stock.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.